Reported Earnings • May 17
First quarter 2026 earnings released: US$0.12 loss per share (vs US$0.23 loss in 1Q 2025) First quarter 2026 results: US$0.12 loss per share. Net loss: US$1.65m (loss widened 60% from 1Q 2025). Tillkännagivande • May 09
Silo Pharma Files Provisional Patent for Ibogaine-Based Therapeutic Targeting Traumatic Brain Injury Silo Pharma, a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced a strategic initiative to explore ibogaine-based therapeutics for the treatment of traumatic brain injury (TBI) and associated neuropsychiatric conditions. Silo has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) titled “Compositions and Methods for Treating Traumatic Brain Injuries and/or Disorders Associated therewith with Ibogaine.” The invention applies to the use of ibogaine and related compounds for the treatment of TBI, post-traumatic stress disorder (PTSD) and associated conditions. Silo’s newest drug discovery initiative is in line with recently published clinical and neuroimaging findings demonstrating substantial improvements in patients with TBI following treatment with ibogaine-based protocols. Reported outcomes include significant reductions in depression and anxiety symptoms, as well as measurable structural brain changes, including increased cortical thickness, subcortical volume expansion, and reductions in predicted brain age following a single treatment. In accordance with the Executive Order by President Trump announced on April 18, 2026, the FDA has granted Breakthrough Therapy designation to specific psychedelic drugs through a program designed to expedite the development and review of drugs intended to treat serious or life-threatening conditions. The Executive Order cites ibogaine’s potential for conditions that persist after standard therapies are completed. Silo will evaluate the potential of ibogaine and related compounds, including differentiated protocols and combination approaches, as part of its broader strategy to develop next-generation psychedelics-assisted CNS therapeutics. The Company intends to explore treatment approaches designed to promote neuroplasticity, improve functional outcomes, and address the underlying pathophysiology of TBI. TBI remains a significant unmet medical need, particularly among military veterans and individuals with chronic neuropsychiatric symptoms. No FDA-approved treatments address structural or regenerative aspects of traumatic brain injury. Current options are limited to symptomatic support. The global traumatic brain injury (TBI) therapeutics market is estimated to reach $6.0 billion by 2032, growing at a CAGR of 6.0% between 2025 and 2032. Key drivers of growth include. The increasing incidence of brain injuries worldwide and rapid advancements in treatment options. Tillkännagivande • May 01
Silo Pharma, Inc. Announces Its PTSD Program Advances as FDA Fast-Tracks Psychedelic Therapies for PTSD Silo Pharma, Inc. commended a wave of coordinated U.S. federal actions that are rapidly advancing the development of psychedelic-based therapeutics for mental health and substance use disorders. Building on last weekend’s executive initiative to fast-track these treatments, multiple agencies have taken meaningful steps this week to accelerate research, clinical progress, and regulatory clarity across the sector. The Advanced Research Projects Agency for Health announced initial awardees under its EVIDENT program, including institutions such as Johns Hopkins University and other innovators focused on psychedelic science. Silo believes this funding validates its position on the growing importance of data-driven approaches to treating complex neurological and psychiatric conditions. In parallel, the U.S. Food and Drug Administration granted investigational new drug (IND) clearance to DemeRx NB for its noribogaine candidate targeting alcohol use disorder, highlighting continued expansion of clinical-stage programs in the mental health space. The FDA issued three Commissioner’s National Priority Vouchers to Compass Pathways, Usona Institute, and Transcend Therapeutics, underscoring a clear intent to accelerate high-impact therapies. Notably, the inclusion of a PTSD-relevant program further signals a strong institutional focus on addressing urgent unmet needs among veterans and broader patient populations. Additionally, the organization confirmed that final guidance for psychedelic drug development will be published imminently, a long-anticipated milestone expected to provide critical clarity for sponsors and researchers navigating clinical and regulatory pathways. Tillkännagivande • Apr 20
Silo Pharma Positioned to Advance Treatment Targeting PTSD as President Trump Signs Executive Order Aimed at Accelerating Research and Treatment Based Upon Psychedelics Silo Pharma, Inc. highlighted the strength and strategic positioning of its pipeline in response to increasing national attention and policy discussion surrounding psychedelic-based treatments for mental health disorders. Silo Pharma’s lead program, SPC-15, is an intranasal prophylactic treatment targeting PTSD, designed to leverage rapid nose-to-brain delivery for enhanced therapeutic effect and patient compliance. The program is being advanced under a 505(b)(2) regulatory pathway, potentially enabling a streamlined development timeline. Key Highlights of SPC-15 (PTSD Program): Designed as a novel serotonin 4 (5-HT4) receptor agonist. Targeting prophylactic treatment of PTSD and stress-induced disorders. Administered via an intranasal formulation designed for rapid CNS delivery. Backed by intellectual property licensed from Columbia University. Preparing for IND engagement with the FDA. Advanced drug delivery strategy. Partnership for optimized intranasal device development. Focus on nose-to-brain delivery platforms, a rapidly emerging segment in CNS therapeutics. Tillkännagivande • Apr 17
Silo Pharma, Inc. has filed a Follow-on Equity Offering. Silo Pharma, Inc. has filed a Follow-on Equity Offering.
Security Name: Series A-1 Warrants
Security Type: Common Stock
Securities Offered: 2,416,670
Security Name: Series A-2 Warrants
Security Type: Common Stock
Securities Offered: 2,356,670 New Risk • Apr 07
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 18% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (18% average weekly change). Earnings have declined by 26% per year over the past 5 years. Shareholders have been substantially diluted in the past year (263% increase in shares outstanding). Revenue is less than US$1m (US$72k revenue). Market cap is less than US$10m (US$5.79m market cap). Tillkännagivande • Apr 07
Silo Pharma Inc Receives European Patent Allowance for Licensed Novel Ptsd Prevention Therapy Silo Pharma, Inc. announced that the European Patent Office (EPO) has issued a Rule 71(3) communication indicating its intent to grant a patent for an European patent application titled “Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress” (European Patent Application No. 20786878.7) that the Company has an exclusive license from Columbia University. The allowed claims cover methods of preventing stress-induced fear and depressive-like behavior and associated affective disorders using selected serotonin 4 (5-HT4) receptor agonists — a differentiated approach targeting pathways associated with stress resilience rather than just symptom management. The patent, once granted, is expected to protect major European markets, further enhancing Silo’s strategic positioning as it advances its pipeline. The Company is evaluating Unitary Patent protection and key national validations to maximize geographic coverage and long-term value. With growing global focus on mental health and stress-related conditions, Silo Pharma continues to build a portfolio targeting next-generation CNS therapeutics with differentiated mechanisms of action. Reported Earnings • Mar 30
Full year 2025 earnings released: US$0.50 loss per share (vs US$1.19 loss in FY 2024) Full year 2025 results: US$0.50 loss per share (improved from US$1.19 loss in FY 2024). Net loss: US$4.23m (loss narrowed 3.8% from FY 2024). Over the last 3 years on average, earnings per share has increased by 26% per year but the company’s share price has fallen by 46% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 24
Silo Pharma, Inc. (NasdaqCM:SILO) announces an Equity Buyback for $1 million worth of its shares. Silo Pharma, Inc. (NasdaqCM:SILO) announces a share repurchase program. Under the program, the company will repurchase up to $1 million of the Company's common stock. As of November 13, 2025, the company had 13,318,273 shares of common stock outstanding. Tillkännagivande • Dec 29
Silo Pharma Receives Non-Compliance Notice from Nasdaq to Regain Compliance with Minimum Bid Price Requirement As previously disclosed in a Current Report on Form 8-K filed by Silo Pharma, Inc. (the “Company”) on June 27, 2025, the Company received a notification (the “Notification Letter”) from The Nasdaq Stock Market, LLC (“Nasdaq”) that it is not in compliance with the minimum bid price requirements set in Nasdaq Listing Rule 5550(a)(2) for continued listing on The Nasdaq Capital Market. Nasdaq Listing Rule 5550(a)(2) requires listed securities to maintain a minimum bid price of $1.00 per share, and Nasdaq Listing Rule 5810(c)(3)(A) provides that a failure to meet the minimum bid price requirement exists if the deficiency continues for a period of 30 consecutive business days. The Company initially had 180 calendar days, or until by December 24, 2025, to regain compliance with the minimum bid price requirement. The Company was unable to regain compliance with the minimum bid price requirement by December 24, 2025. On December 24, 2025, the Company received a letter (the “Extension Notice”) from Nasdaq notifying the Company that its request for an extension to regain compliance with the minimum bid price requirement has been granted, and the Company has an additional 180 calendar days, or until June 22, 2026, to regain compliance with the minimum bid price requirement. Nasdaq’s determination was based on the Company meeting the continued listing requirement for market value of publicly held shares and all other applicable requirements for initial listing on the Nasdaq Capital Market with the exception of the bid price requirement, and the Company’s written notice of its intention to cure the deficiency during the second compliance period by effecting a reverse stock split, if necessary. The Extension Notice has no immediate effect on the listing or trading of the Company’s common stock on The Nasdaq Capital Market and, at this time, the Company’s common stock will continue to trade on The Nasdaq Capital Market under the symbol “SILO.” If at any time before June 22, 2026, the bid price of the Company’s common stock closes at or above $1.00 per share for a minimum of 10 consecutive business days, Nasdaq will notify the Company that it is in compliance with the minimum bid price requirement. However, if compliance with the minimum bid price requirement cannot be demonstrated by June 22, 2026, Nasdaq will notify the Company that its common stock will be delisted from The Nasdaq Capital Market, at which time, the Company may appeal Nasdaq’s determination to a Hearings Panel. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider implementing available options, including, but not limited to, implementing a reverse stock split of its outstanding securities during the second compliance period, to regain compliance with the minimum bid price requirement under the Nasdaq Listing Rules. Tillkännagivande • Nov 18
Silo Pharma Partners with Allucent to Support Planned Fda Investigational New Drug Application for Spc-15 as A Therapeutic for Ptsd Silo Pharma, Inc. announced that it has selected Allucent, a global full-service clinical research organization (CRO), to support the Company's final preparations and planned submission of its investigational new drug application (IND) to the FDA for a Phase 1 clinical trial of its intranasal prophylactic SPC-15 as a treatment for PTSD. The Company currently expects to submit the IND in 2026 and commence its first-in-human (FIH) SPC-15 trial subsequent to FDA approval. Data from an IND-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetic study, along with findings from a drug-device study of the formulation-specific intranasal spray system used for SPC-15 drug delivery, are expected in early 2026. Silo intends to pursue the FDA's 505(b)(2) accelerated regulatory pathway for clinical development of SPC-15. Reported Earnings • Nov 16
Third quarter 2025 earnings released: US$0.12 loss per share (vs US$0.22 loss in 3Q 2024) Third quarter 2025 results: US$0.12 loss per share. Net loss: US$1.11m (loss widened 20% from 3Q 2024). Tillkännagivande • Oct 02
Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million. Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,857,143
Price\Range: $0.875
Discount Per Security: $0.065625
Transaction Features: Registered Direct Offering Tillkännagivande • Sep 30
Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.5 million. Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.5 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,857,143
Price\Range: $0.875
Transaction Features: Registered Direct Offering Tillkännagivande • Sep 08
Silo Pharma, Inc., Annual General Meeting, Oct 24, 2025 Silo Pharma, Inc., Annual General Meeting, Oct 24, 2025. Location: 677n washington boulevard, florida 34236, sarasota United States Tillkännagivande • Aug 22
Silo Pharma, Inc. Announces the Publication of Preclinical Research for Its Alzheimer's Disease Therapeutic, Spc-14 Silo Pharma, Inc. announced the publication of preclinical research for its Alzheimer's disease (AD) therapeutic, SPC-14, in Alzheimer's Research & Therapy, an international open-access peer-reviewed scientific journal known as the major forum for translational research into AD. The study, titled "Combinatorial targeting of NMDARs and 5-HT4Rs exerts beneficial effects in a mouse model of Alzheimer's disease," details research methods and results indicating that the combined administration of (R,S) -ketamine with prucalopride is a novel multi-modal therapeutic strategy to treat cognitive decline in AD. The Company's CEO, Eric Weisblum, was a co-author of the study and the project was supported by a sponsored research program from the Company. SPC-14 was developed under a sponsored research agreement with Columbia University. In 2024, Silo entered into an exclusive global license agreement with Columbia University under which it is authorized to further develop, manufacture, and commercialize SPC-14. SPC-14 addresses a vast Alzheimer's disease treatment market projected to grow to $30.8B in 2033, at 18.8% CAGR.1 About SPC-14: SPC-14 is a novel intranasal therapeutic that targets glutamate receptor NDMAR and serotonin type 4 receptor 5HT4 to treat cognitive and neuropsychiatric symptoms in Alzheimer's disease. In the latest small animal preclinical study, SPC-14 was effective against LH (luteinizing hormone) stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia, a measure of anxiety. Tillkännagivande • Aug 19
Silo Pharma's PTSD Candidate SPC-15 Achieves Positive Safety Milestone, Paving Way for Accelerated Clinical Trials Under 505(b)(2) Pathway Silo Pharma, Inc. announced positive bioanalytical and safety/toxicology results for its U.S. Food and Drug Administration (FDA)-requested 7-day large animal safety study of its lead asset SPC-15. The preclinical study compared the safety and overall exposure of the SPC-15 intranasal spray formulation (intended for clinical use) to oral drug administration. Data showed that SPC-15, administered at clinical-representative doses, demonstrated local and systemic safety with no toxicities identified. The study also showed that systemic exposure of intranasal SPC-15 administered at the anticipated therapeutic range is comparable to standard oral administration, which believe validates the drug's potential as a targeted intranasal therapeutic for PTSD and stress-induced anxiety that has a potentially greater safety profile. In opinion, the study data further supports Silo's planned 505(b)(2) regulatory strategy for its SPC-15 program. This regulatory route allows companies to utilize previously established safety and efficacy data (from approved drugs) to potentially streamline the FDA drug approval process and reduce drug development costs. Silo is currently conducting an IND-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetic animal study of SPC-15, and a device study of the formulation-specific microchip-based nasal spray system. The Company is also evaluating potential clinical CRO sites for first-in-human trials. The post-traumatic stress disorder market size reached a value of $1.8 billion in 2024. Looking forward, the market is expected to reach $3.2 billion by 2034 due to increasing focus on mental health support and the need for personalized treatments and integrated care solutions. Reported Earnings • Aug 14
Second quarter 2025 earnings released: US$0.19 loss per share (vs US$0.30 loss in 2Q 2024) Second quarter 2025 results: US$0.19 loss per share. Net loss: US$1.20m (loss widened 29% from 2Q 2024). Tillkännagivande • Aug 05
Silo Pharma, Inc. Appoints Corwin Yu as the First Member of Its Newly Formed Crypto Advisory Board Silo Pharma, Inc. has appointed digital asset tech pioneer, Corwin Yu, as the first member of its newly formed Crypto Advisory Board to lead this new strategy. To further this initiative, Silo has recently acquired market intelligence technology powered by artificial intelligence, equipping the team with real-time insights to potentially drive smarter, faster decision-making. Corwin Yu is a senior technology and trading executive with over 20 years of experience building and managing mission-critical systems for institutional finance. Mr. Yu currently serves as Global Head of Digital Assets at fintech company TSImagine, and previously he was the founding Chief Technology Officer of MARKTS, one of the first institutional crypto trading platforms. In addition to these leadership roles, his prior experience spanned PIMCO, Credit Suisse, hedge funds and digital asset firms. As a proven leader in cryptocurrency trading infrastructure, fund management, and regulatory compliance, Mr. Yu has an extensive background in deploying scalable cloud-native platforms and overseeing cross-asset trading strategies. His track record includes founding and scaling digital asset trading platforms, managing global engineering and DevOps teams, and delivering secure and compliant crypto custody and treasury solutions. Tillkännagivande • Jul 07
Silo Pharma Advances PTSD Drug SPC-15 Toward Planned 2025 Ind Submission with Pre-Clinical Study Data Expected in Third Quarter 2025 Silo Pharma, Inc. announced that it expects to receive data from the additional preclinical studies of its lead asset SPC-15 within the next 30 to 90 days. SPC-15 is a novel intranasal prophylactic targeting Post-Traumatic Stress Disorder (PTSD). The final drug studies are 1) an investigational new drug (IND)-enabling GLP (Good Laboratory Practice) -compliant toxicology and toxicokinetic animal study, and 2) a U.S. Food and Drug Administration (FDA) requested 7-day safety and toxicology large animal study. Concurrently, a device study of the formulation-specific microchip-based nasal spray system used in SPC-15 is being conducted. Early data on SPC-15 indicated that its optimized patient safety profile and therapeutic delivery may provide additional benefits for combating stress-induced pathophysiology at both the behavioral and neural levels. Only two drugs are currently approved by the FDA for treating PTSD, both of which primarily target theressive effects of the condition. In contrast, SPC-15's differentiated method of action is designed to increase stress resilience in high-risk populations. There have been no new drug approvals in nearly 25 years for the condition that affects an estimated 3.9% of the world's population. SPC-15 is an intranasal 5-HT4 receptor agonist aimed at treating stress-induced psychiatric disorders such as PTSD and anxiety. With its potential eligibility for the FDA's streamlined 505(b)(2) regulatory pathway, SPC-15 offers a promising approach to accelerate the approval process. Silo Pharma is collaborating with Columbia University to conduct preclinical studies and has exclusive global rights to the development and commercialization of SPC-15. Tillkännagivande • May 17
Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.999942 million. Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $1.999942 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 2,723,336
Price\Range: $0.6
Discount Per Security: $0.045
Security Name: Series A-1 Warrants
Security Type: Equity Warrant
Securities Offered: 3,333,338
Security Name: Series A-2 Warrants
Security Type: Equity Warrant
Securities Offered: 3,333,338
Security Name: Pre-Funded Warrants
Security Type: Equity Warrant
Securities Offered: 610,002
Price\Range: $0.5999
Discount Per Security: $0.045 Reported Earnings • May 12
First quarter 2025 earnings released: US$0.23 loss per share (vs US$0.28 loss in 1Q 2024) First quarter 2025 results: US$0.23 loss per share. Net loss: US$1.03m (loss widened 29% from 1Q 2024). Tillkännagivande • Apr 30
Silo Pharma, Inc.'S SP-26 Ketamine Implant Meets All Endpoints in Fibromyalgia Study Silo Pharma, Inc. announced positive results for its preclinical study evaluating SP-26, a novel extended-release ketamine implant which it believes supports SP-26's potential as a safe, well-tolerated, and long-acting treatment for fibromyalgia. All study endpoints were met, including survival, clinical observations, body weight stability, neurological assessments, and histopathological evaluation. The study, which was conducted in minipigs, evaluated the pharmacokinetics, safety, and local tolerability of SP-26 formulations when administered subcutaneously. SP-26 implants are designed to deliver ketamine at a controlled rate, avoiding the dissociative effects associated with IV bolus injection and providing a viable alternative to highly addictive opioid treatments. The preclinical results position Silo to advance toward clinical studies and expand the Company's pipeline for chronic pain and mental health indications. Study Highlights: Safety Profile: No implant-related adverse events were observed. Animal maintained a healthy weight, normal neurological behavior, and full survival to study conclusion. Sustained Drug Release: Ketamine was steadily released post-implantation, with measurable systemic exposure achieved across all dose levels. Peak drug levels were reached within 1 hour in most subjects, with sustained plasma concentrations observed for up to 22 days. Minimal Tissue Reaction: Both formulations elicited only minimal to mild chronic inflammation at the implant sites, with no dose-dependent or formulation-specific differences. "SP-26 has been designed to offer a new approach to pain management by providing sustained, sub-psychedelic levels of ketamine in an abuse-deterrent format," Weisblum added. "Preclinical SP-26 research overall has focused on ensuring that the safety profile of SP-26 aligns with FDA requirements for potential at-home therapeutic designation. If approved, SP-26 could become the first at-home injectable ketamine-based therapeutic. SP-26 is a ketamine-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia. The subcutaneous implant is being designed to safely regulate dosage and time release of the pain-relieving treatment. If clinically successful, SP-26 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval. Tillkännagivande • Apr 28
Silo Pharma, Inc. Expands Intellectual Property Portfolio with Patent Application for Exclusively Licensed Alzheimer's Drug Silo Pharma, Inc. announced the filing of a patent application with the U.S. Patent and Trademark Office (USPTO) focused on the neurology drug SPC-14, an intranasal compound for the treatment of Alzheimer's disease (AD) exclusively licensed to Silo Pharma from Columbia University. The patent, titled "Compositions and Methods for the Treatment of Alzheimer's Disease and Other Neurogenerative Disease," covers SPC-14's novel mechanism of action for targeting glutamate receptor NDMAR and serotonin 5-HT4 to address cognitive and neuropsychiatric symptoms in AD. By targeting the two receptor molecules, the drug has shown efficacy against luteinizing hormone (LH) in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety). SPC-14 was developed under a sponsored research agreement with Columbia University. In 2024, Silo entered into an exclusive global license agreement with Columbia University under which it is authorized to further develop, manufacture, and commercialize the drug SPC-14. Reported Earnings • Mar 30
Full year 2024 earnings released: US$1.19 loss per share (vs US$1.18 loss in FY 2023) Full year 2024 results: US$1.19 loss per share (further deteriorated from US$1.18 loss in FY 2023). Net loss: US$4.39m (loss widened 21% from FY 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 11 percentage points per year, which is a significant difference in performance. Tillkännagivande • Mar 27
Silo Pharma, Inc. Achieves Key Milestone with First Dosing in IND-Enabling GLP Study for SPC-15 as a Groundbreaking PTSD Treatment Silo Pharma, Inc. announced first dosing in an investigational new drug (IND)-enabling GLP (Good Laboratory Practice)-compliant toxicology and toxicokinetics study of its lead asset, SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD). Silo Pharma completed a pre-IND meeting in September 2024 to align with the FDA on the 505(b)(2) regulatory pathway for approval of SPC-15 and review the Company's proposed plan to support opening an IND. The FDA's 505(b) drug development route can significantly shorten clinical timelines for FDA approval and reduce drug development costs. Tillkännagivande • Feb 27
Silo Pharma Granted U.S. Patent for Novel Intranasal Post-Traumatic Stress Disorder Treatment Silo Pharma, Inc. announced that the U.S. Patent and Trademark Office (USPTO) issued an Issue Notification for previously filed patent application (No. 17/954,864) titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders in Females.” The projected patent number is 12,239,614 and the issue date of such patent will be March 4, 2025. The patent reinforces protection for Silo’s lead asset, SPC-15, an intranasal treatment targeting post-traumatic stress disorder (PTSD). The patent includes newly added claims to U.S. Patent 11,491,120, which was issued to Silo in November 2022. Tillkännagivande • Feb 19
Silo Pharma Expands Intellectual Property Portfolio with Provisional Patent Filing for Innovative SPC-15 Combination Treatment Silo Pharma, Inc. announced the filing of a provisional patent application with the U.S. Patent and Trademark Office (USPTO) for its lead asset SPC-15. Silo currently has patents issued and numerous expanded patent applications pending for SPC-15, a technology that was originally licensed through a collaboration with Columbia University. The provisional patent covers a dual-action method and composition for combating stress-induced pathophysiology and reducing a variety of stress-induced psychiatric behaviors. A preclinical study of SPC-15, a serotonin type IV receptor (5-HT4R) agonist, combined with an N-methyl-D-aspartate receptor (NMDAR) antagonist demonstrated significant improvement in behavioral outcomes and a marked reduction in severe stress-induced conditions. Tillkännagivande • Feb 11
Silo Pharma, Inc. Announces Positive Initial Pharmacokinetic, Safety, and Tolerability Study of SP-26 for Chronic Pain and Fibromyalgia Silo Pharma, Inc. announced a positive update from an ongoing study evaluating the pharmacokinetics, safety and tolerability of its novel SP-26 ketamine extended-release rods when implanted subcutaneously. The SP-26 implant is a novel self-administered, non-opioid therapeutic intended for the treatment of chronic pain and fibromyalgia. The launch of non-GLP study in December 2024 marked the first small animal testing of SP-26, a key preclinical milestone. Implantation (dosing) was completed in the first week of January 2025 and no animals experienced serious side effects or discomfort. Absorption, distribution, metabolism, and excretion (ADME) testing is nearing completion and final safety, and pharmacokinetic reports are expected in March 2025. SP-26 is a ketamine-based injectable dissolvable polymer implant for the treatment of chronic pain and fibromyalgia. The subcutaneous implant is being designed to safely regulate dosage and time release of the pain-relieving treatment. If clinically successful, SP-26 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. New Risk • Jan 16
New major risk - Shareholder dilution The company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 45% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (20% average weekly change). Earnings have declined by 17% per year over the past 5 years. Shareholders have been substantially diluted in the past year (45% increase in shares outstanding). Revenue is less than US$1m (US$72k revenue). Market cap is less than US$10m (US$8.07m market cap). Tillkännagivande • Dec 19
Silo Pharma Initiates Pharmacokinetic and Tolerability Study for Sp-26 Targeting Chronic Pain and Fibromyalgia Silo Pharma, Inc. announced the initiation of a pharmacokinetic and tolerability study in partnership with its contract research organization, AmplifyBio. The study is designed to assess the pharmacokinetics of Silo’s dissolvable ketamine-based injectable implant, SP-26, in a minipig model. SP-26 is being developed as a self-administered, non-opioid therapeutic aimed at treating chronic pain and fibromyalgia. The non-GLP study, set to span three weeks, will investigate the absorption, distribution, metabolism, and excretion of extended-release ketamine hydrochloride implants. Two distinct polymer formulations will be tested at varying dose levels. Tillkännagivande • Nov 19
Silo Pharma, Inc. Announces Positive Results for Novel Spc-15 Treatment Targeting Stress-Related Disorders Silo Pharma, Inc. announced promising results from a preclinical study on SPC-15. This new formulation, which targets both the serotonin 5-HT4 receptor (5-HT4R) and the NMDA receptor (NMDAR), has shown potential as a treatment for major depressive disorder (MDD), and other severe stress-related conditions. The study highlights the proposed efficacy of combining SPC-15, a 5-HT4R agonist, with an NMDAR antagonist to treat stress-induced behaviors. Results from animal models indicate that this dual-target approach may offer additional efficacy in treating severe conditions compared to using either agent alone, suggesting a potential enhanced therapeutic effect for managing severe psychiatric conditions. Key Study Findings: Dual Receptor Targeting Yields Superior Results: By simultaneously targeting 5-HT4R and NMDAR, the combined treatment demonstrated significant improvement in behavioral outcomes related to severe stress-induced conditions as compared to using either agent alone. Additive Therapeutic Effects: The combination therapy showed a marked reduction in stress behaviors in animal models, indicating potential benefits for patients suffering from treatment-resistant depression. SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for the treatment of PTSD, anxiety, and other stress-induced affective disorders. SPC-15 is being developed as an intranasal medication. If clinically successful, SPC-15 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval. Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University and was granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. Reported Earnings • Nov 14
Third quarter 2024 earnings released: US$0.22 loss per share (vs US$0.21 loss in 3Q 2023) Third quarter 2024 results: US$0.22 loss per share (further deteriorated from US$0.21 loss in 3Q 2023). Net loss: US$928.8k (loss widened 41% from 3Q 2023). Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 24 percentage points per year, which is a significant difference in performance. Tillkännagivande • Nov 02
Silo Pharma, Inc. Reports Positive Results in Sterilization and Dissolution Testing of SP-26 Ketamine Implant Silo Pharma, Inc. announced promising results from recent sterilization and dissolution tests of its SP-26 ketamine-loaded implant for fibromyalgia and chronic pain. These tests were conducted under the Company’s current development agreement with Sever Pharma Solutions. Previously, Silo disclosed that Sever Pharma Solutions initiated the scale-up, extrusion, and analytical testing of the SP-26 ketamine hydrochloride (ketamine HCL) polymer implants. This sterilization and dissolution testing utilized the time-released, dose-controlled formulation chosen by Silo for ongoing preclinical research. The analysis of the implants thus far has demonstrated a sustained 80%+ drug release over a 7-day period, highlighting consistent drug delivery. Additionally, the implants showed minimal variation in key physical properties, underscoring the safety and stability of the formulation. Tillkännagivande • Sep 20
Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024 Silo Pharma, Inc., Annual General Meeting, Nov 12, 2024. Location: 677 n washington boulevard, florida 34236., sarasota United States Reported Earnings • Aug 15
Second quarter 2024 earnings released: US$0.30 loss per share (vs US$0.32 loss in 2Q 2023) Second quarter 2024 results: US$0.30 loss per share (improved from US$0.32 loss in 2Q 2023). Net loss: US$931.8k (loss narrowed 8.0% from 2Q 2023). Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has only fallen by 44% per year, which means it has not declined as severely as earnings. Tillkännagivande • Jul 23
Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.100005 million. Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.100005 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 763,638
Price\Range: $2.75
Discount Per Security: $0.20625
Transaction Features: Registered Direct Offering Tillkännagivande • Jul 20
Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.100005 million. Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.100005 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 763,638
Price\Range: $2.75
Transaction Features: Registered Direct Offering Tillkännagivande • Jun 13
Silo Pharma, Inc. announced that it has received $2.077409 million in funding On June 11, 2024, Silo Pharma, Inc. closed the transaction. The transaction included participation from three investors. New Risk • Jun 09
New minor risk - Shareholder dilution The company's shareholders have been diluted in the past year. Increase in shares outstanding: 17% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (US$72k revenue). Market cap is less than US$10m (US$4.28m market cap). Minor Risk Shareholders have been diluted in the past year (17% increase in shares outstanding). Tillkännagivande • Jun 08
Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.000002 million. Silo Pharma, Inc. has completed a Follow-on Equity Offering in the amount of $2.000002 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 917,432
Price\Range: $2.18
Transaction Features: Registered Direct Offering Tillkännagivande • Jun 06
Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.000002 million. Silo Pharma, Inc. has filed a Follow-on Equity Offering in the amount of $2.000002 million.
Security Name: Common Stock
Security Type: Common Stock
Securities Offered: 917,432
Price\Range: $2.18
Transaction Features: Registered Direct Offering New Risk • Jun 05
New major risk - Share price stability The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of American stocks, typically moving 16% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (16% average weekly change). Earnings have declined by 14% per year over the past 5 years. Revenue is less than US$1m (US$72k revenue). Market cap is less than US$10m (US$6.31m market cap). Tillkännagivande • Jun 05
Silo Pharma Submits Pre-Investigational New Drug Application to FDA for SPC-15 as a Treatment for PTSD and Anxiety Silo Pharma, Inc. announced its submission of a pre-Investigational New Drug (pre-IND) briefing package and meeting request to the U.S. Food and Drug Administration for SPC-15, Silo’s intranasal prophylactic treatment for post-traumatic stress disorder and stress-induced anxiety disorder. Pre-clinical data indicate that SPC-15 has additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels. The Company recently announced positive results, including effective and consistent exposure from intranasal administration of SPC-15, from a non-GLP (good laboratory practice) small animal dose-ranging study completed in February 2024. In accordance with a sponsored research agreement with Columbia University, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. The Company expects to finalize and enter into the exclusive license agreement in the first half of 2024. Next steps for Silo’s SPC-15 program include a progressive intellectual and neurological deterioration (PIND) study followed by a GLP study, both slated to commence in the second half of 2024. Both studies are required steps before submission of an Investigational New Drug (IND) application to the FDA. Only two drugs are currently approved by the FDA for treating PTSD, both of which primarily target the depressive effects of the condition. In contrast, SPC-15’s differentiated method of action is designed to increase stress resilience in high-risk populations. SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for the treatment of PTSD, anxiety, and other stress-induced affective disorders. SPC-15 is being developed as an intranasal medication. If clinically successful, SPC-15 could qualify for the FDA’s streamlined 505(b)(2) regulatory pathway for drug approval. Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University under a sponsored research agreement and option. Tillkännagivande • May 23
Silo Pharma, Inc. Announces Positive Results from Study for Depression Treatment, Remission, and Relapse Prevention Silo Pharma, Inc. announced new results in its research focused on depression remission and relapse prevention. A recent study under the Company’s sponsored research agreement with Columbia University suggested a potentially innovative drug formulation that targets biochemical pathways associated with mood regulation previously unexplored by the Company which showed positive effects including marked improvements in patient mood stability without the side effects commonly associated with existing antidepressants. The company has successfully taken SPC-15 through pre-clinical development and is preparing to submit a pre-investigational New Drug Application (IND) to the FDA for the drug’s lead indication in PTSD. Silo has exercised its option to license SPC-15 from Columbia University, pursuant to a sponsored research and option agreement originally established in 2021. Under the terms of the license agreement, which is currently being finalized, Silo will be granted an exclusive license to further develop, manufacture, and commercialize SPC-15 worldwide. The Company expects to complete and enter into the exclusive license agreement in the first half of 2024. Reported Earnings • May 15
First quarter 2024 earnings released: US$0.28 loss per share (vs US$0.29 loss in 1Q 2023) First quarter 2024 results: US$0.28 loss per share (improved from US$0.29 loss in 1Q 2023). Net loss: US$801.7k (loss narrowed 12% from 1Q 2023). Revenue is forecast to stay flat during the next 3 years compared to a 18% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 22% per year but the company’s share price has fallen by 48% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Apr 24
Silo Pharma, Inc. Announces Positive Results for Intranasal PTSD Treatment Silo Pharma, Inc. announced positive data in the final validation report from the recent pharmacokinetic (PK) study of SPC-15, an intranasal prophylactic treatment for anxiety and post-traumatic stress disorder (PTSD). The PK study was conducted as part of non-GLP small animal dose-ranging study of SPC-15 completed in February 2024. The activity of SPC-15 in the subjects or the PK study was evaluated over a 7-day repeat intranasal dose, including the processes of absorption, distribution, and excretion. Time to peak drug concentration (Tmax) occurred between 0.5 and 2 hours following intranasal administration compared to 2 hours following oral gavage administration. In previous findings from the non-GLP study, SPC-15 demonstrated rapid absorption with good exposure over a full 24-hour period, and based on these studies determined an optimal once-per-day human intranasal dosing. Now completed, the non-GLP study will be followed by a progressive intellectual and neurological deterioration (PIND) study and then a GLP study, both slated to commence in 2024, and both of which are additional required steps before submission of an Investigational New Drug (IND) application for SPC-15 to the FDA. SPC-15 is a novel serotonin 4 (5-HT4) receptor agonist that utilizes biomarkers for the treatment of PTSD, anxiety, and other stress-induced affective disorders. SPC-15 is being developed as an intranasal medication. If clinically successful, SPC-15 could qualify for the FDA's streamlined 505(b)(2) regulatory pathway for drug approval. Silo Pharma is conducting preclinical studies of SPC-15 in collaboration with Columbia University under a sponsored research agreement and option. Reported Earnings • Mar 26
Full year 2023 earnings: EPS misses analyst expectations Full year 2023 results: US$1.18 loss per share (improved from US$1.71 loss in FY 2022). Net loss: US$3.63m (loss narrowed 7.1% from FY 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 18%. Revenue is forecast to stay flat during the next 3 years compared to a 17% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has fallen by 6% per year but the company’s share price has fallen by 49% per year, which means it is performing significantly worse than earnings. Tillkännagivande • Feb 16
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery Silo Pharma, Inc. provided a positive update on SP-26, its novel time-released, dose-controlled formulation of ketamine initially targeted for fibromyalgia. A pre-clinical research study is underway involving analytical testing services and small batch proof-of-concept extrusion trials to determine drug release and stability. In recent testing, SP-26 polymer implants were blended with ketamine hydrochloride (ketamine HCL) in two loadings, 20% and 40%. Measurements and analysis demonstrated that the drug was successfully loaded into the engineered particles to encapsulate the implantable treatment. The structural stability and integrity of both the 20% and 40% loaded implants were maintained, with no leakage, degradation, or discoloration. Tillkännagivande • Feb 03
Silo Pharma, Inc. Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology Silo Pharma, Inc. announced updates for its strategic 2024 focus for its clinical pipeline. The Company is advancing a diversified portfolio of four drugs targeting three health areas: mental health, chronic pain, and neurology. Silo’s lead program, SPC-15, is an intranasal prophylactic treatment for the treatment of PTSD and stress-induced anxiety disorder, an underserved market with few approved drugs. A dose-ranging non GLP study of SPC-15 is in progress, with a final validation report expected in the first half of 2024. With PTSD affecting 3.5%1 of U.S. adults and few approved drugs, SPC-15's method of action could offer a new and much-needed treatment solution. Silo's next prioritized program is SP-26, an innovative non-opioid chronic pain solution, developed as an injectable and dissolvable time-release ketamine-loaded implant for fibromyalgia, utilizing the subcutaneous injection method. As a self-administered treatment, SP-26 holds the potential to be the first at-home ketamine treatment approved for chronic pain management. Silo's collaboration with Columbia University has also produced SPC-14, a nascent Alzheimer’s disease therapeutic. With initial positive results from animal studies and more data expected in 2024, Silo believes SPC-14 represents an encouraging development in Alzheimer’s disease research. SPU-16, targeting multiple sclerosis (MS), is being developed in collaboration with the University of Maryland, Baltimore (UMB). The novel homing peptide is designed to cross the blood-brain barrier and target damaged tissue and inflammation. Silo plans to utilize the FDA’s streamlined 505(b)(2) pathway for drug approval. This approach, allowing the inclusion of external safety and efficacy data in INDs, is expected to expedite the approval process and can reduce development costs significantly. Through its collaborations with Columbia University and UMB, Silo aims to leverage this pathway for each of SPC-15, SP-26, and SPC-14. Tillkännagivande • Jan 25
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study Silo Pharma, Inc. announced that its Alzheimer’s disease therapeutic SPC-14 showed positive efficacy in small animals. Data from a study conducted at Columbia University in collaboration with Silo Pharma showed that SPC-14 was effective against LH stress in attenuating learned helplessness, perseverative behavior, and hyponeophagia (a measure of anxiety). The mice were treated twice daily with the SPC-14 therapeutic. Tillkännagivande • Jan 05
Silo Pharma Successfully Completes First Phase of Dose-Ranging Study of SPC-15 an Intranasal Treatment for PTSD Silo Pharma, Inc. provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD). The purpose of the study is to identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range with the goal of bringing closer to human trials. The six- to eight-week non-GLP study includes single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study. In the first phase of the study, all of the animals observed to tolerate the intranasal dosing procedure well, with minimal struggling and no sneezing observed. The final validation report is expected in the first quarter of 2024. Pre-clinical data has shown that SPC-15 has additive benefits for combating stress-induced pathophysiology, both at the behavioral and neural levels. Pre-clinical collaborative work with Columbia University will be coupled with published preclinical data in a pre-IND application to the FDA, which the Company expects to submit during the first quarter of 2024. New Risk • Nov 29
New minor risk - Share price stability The company's share price has been volatile over the past 3 months. It is more volatile than 75% of American stocks, typically moving 10% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings are forecast to decline by an average of 48% per year for the foreseeable future. Revenue is less than US$1m (US$72k revenue). Market cap is less than US$10m (US$5.03m market cap). Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (US$14m net loss in 3 years). Share price has been volatile over the past 3 months (10% average weekly change). Reported Earnings • Nov 16
Third quarter 2023 earnings: EPS exceeds analyst expectations Third quarter 2023 results: US$0.21 loss per share (improved from US$0.49 loss in 3Q 2022). Net loss: US$660.2k (loss narrowed 33% from 3Q 2022). Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 32%. Revenue is forecast to stay flat during the next 3 years compared to a 15% growth forecast for the Biotechs industry in the US. Over the last 3 years on average, earnings per share has increased by 11% per year but the company’s share price has fallen by 57% per year, which means it is significantly lagging earnings. Tillkännagivande • Nov 09
Silo Pharma, Inc. to Initiate Dose-Ranging Study of Novel Intranasal Therapeutic SPC-15 for the Treatment of PTSD Silo Pharma, Inc. announced plans to initiate a dose-ranging study of its targeted prophylactic treatment SPC-15 for the treatment of post-traumatic stress disorder (PTSD). The study will identify the maximum tolerated intranasal dose of the drug and pharmacokinetic in small animals to determine the therapeutically relevant dose range. In collaboration with AmplifyBio, Silo Pharma's contract research organization (CRO) partner, the six- to eight-week non-good laboratory practice (GLP) study will include single ascending dose evaluation (phase 1) and a 7-day repeat intranasal dose toxicity and pharmacokinetic study. The final validation report is expected in 2024. Tillkännagivande • Oct 25
Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023 Silo Pharma, Inc., Annual General Meeting, Dec 04, 2023, at 11:00 Eastern Standard Time. Location: satellite office located at 677 N Washington Boulevard, Sarasota Florida United States Agenda: To elect four (4) members to Board of Directors; To approve the Silo Pharma, Inc. Amended and Restated 2020 Omnibus Equity Incentive Plan; To authorize the reincorporation of the Company from the State of Delaware to the State of Nevada (the “Reincorporation”); To approve an amendment to the Company’s Amended and Restated Certificate of Incorporation to decrease the number of authorized shares of common stock of the Company from 500,000,000 to 100,000,000 (the “Share Decrease Proposal”); and to discuss other matters. Tillkännagivande • Oct 17
Silo Pharma’s SPU-21 Peptide Shows Positive Results Against Rheumatoid Arthritis Silo Pharma, Inc. announced positive data from a preclinical study investigating the binding affinity and optimization of SPU-21 liposomal joint homing peptide in human synovial tissue surrounding joints and tendons. SPU-21 selectively targets inflamed synovial tissue to inhibit the progression of rheumatoid arthritis (RA). The University of Maryland, Baltimore (UMB) is Silo Pharma’s collaboration partner for SPU-21 development. In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide targeting multiple sclerosis (MS) and other rare neurological diseases designated. Tillkännagivande • Sep 21
Silo Pharma, Inc. Announces Positive Data on SPC-15 for PTSD and Prepares to File Pre-Investigational New Drug Application with FDA Silo Pharma, Inc. announced that based on positive SPC-15 pre-clinical data, it is working with Kymanox as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA). SPC-15 is a targeted intranasal prophylactic intended for the treatment and prevention of anxiety, PTSD, and other stress-related disorders. Kymanox, a full-service life sciences solutions provider, will provide regulatory affairs support to the Company including the development of a clinical pharmacology and biopharmaceutics strategy and program to be proposed to the FDA. A pre-IND meeting request for collaborative discussions with the FDA will be filed early 2024. SPC-15 utilizes metabolic biomarker profiling to treat anxiety, PTSD, and other stress-related disorders. Its core technology, which is patent-protected, predicts levels of severity and progression of such disorders and informs their response to pharmacological treatments and prevention. Kymanox is a life science professional services organization that offers engineering, scientific, project management, quality, human factors, testing /QC, CQV, and regulatory support to companies exclusively in the biotechnology, pharmaceutical, medical device, and combination product industries. With its diverse team of experts, Kymanox helps clients navigate commercialization challenges that arise throughout a product’s life cycle – from early development to post-market – with optimized safety, quality, efficacy, and accessibility. Kymanox was founded in 2004 and is headquartered in Morrisville, North Carolina USA. Tillkännagivande • Sep 14
Silo Pharma, Inc. Initiates Feasibility Study of SPC-15 Novel Intranasal Formulation for PTSD Silo Pharma, Inc. announced the initiation of an exploratory feasibility study evaluating a selected delivery mechanism for its intranasal therapeutic drug SPC-15. The Company's collaboration partner for the study is a developer and manufacturer of innovative drug delivery systems and technology. SPC-15, a Serotonin 4 receptor agonist with prophylactic efficacy against stress, utilizes biomarkers for the treatment of stress-induced affective disorders, anxiety, and PTSD. Its core technology is patent-protected. Reported Earnings • Aug 13
Second quarter 2023 earnings released: US$0.32 loss per share (vs US$0.33 loss in 2Q 2022) Second quarter 2023 results: US$0.32 loss per share. Net loss: US$1.01m (loss widened 54% from 2Q 2022). Reported Earnings • May 14
First quarter 2023 earnings released: US$0.29 loss per share (vs US$0.31 loss in 1Q 2022) First quarter 2023 results: US$0.29 loss per share. Net loss: US$906.4k (loss widened 50% from 1Q 2022). Tillkännagivande • May 10
Silo Pharma, Inc. Announces Spc-15 Awarded U.S. Patent Protecting Ongoing R&D of Therapeutic for Stress-Induced Affective Disorder and Alzheimer’S Disease Silo Pharma, Inc. announced that the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent 11,622,948 titled “Biomarkers for Efficacy of Prophylactic Treatments Against Stress-Induced Affective Disorders.” The new patent claims cover the use of biomarkers in determining the efficacy of the Company’s portfolio drug SPC-15, a targeted prophylactic treatment utilizing ketamine compositions, as a method of treatment for a stress-induced affective disorder or stress-induced psychopathology. Silo Pharma owns an option to license certain assets of which the patent forms a part currently undergoing studies at Columbia University for stress-induced affective disorders and Alzheimer's disease. Reported Earnings • Mar 27
Full year 2022 earnings released: US$1.71 loss per share (vs US$1.45 profit in FY 2021) Full year 2022 results: US$1.71 loss per share (down from US$1.45 profit in FY 2021). Net loss: US$3.91m (down 242% from profit in FY 2021). Over the last 3 years on average, earnings per share has increased by 54% per year but the company’s share price has fallen by 48% per year, which means it is significantly lagging earnings. Tillkännagivande • Feb 15
Silo Pharma Announces Filing of Patent for Treatment of Alzheimer's Silo Pharma, Inc. announced that it has filed a provisional patent application for the use of its central nervous system (CNS) homing peptides to treat Alzheimer's disease and the onset of dementia. Alzheimer's disease has proven to be a progressive neurodegenerative disorder that is associated with the destruction of higher brain structures, such as those involved in cognition and memory function. The disease leads to deficits and declines in memory, learning, language, and in the ability to perform intentional and purposeful movements. Alzheimer's disease is also accompanied by concomitant behavioral, emotional, interpersonal, and social deterioration. Treatment of Alzheimer's remains largely inadequate. Tillkännagivande • Feb 01
Silo Pharma, Inc. (NasdaqCM:SILO) announces an Equity Buyback for $1 million worth of its shares. Silo Pharma, Inc. (NasdaqCM:SILO) announces a share repurchase program. Under the program, the company will repurchase up to $1 million worth of its common stock. As of November 10, 2022, the company had 3,138,797 million shares of common stock outstanding. Tillkännagivande • Jan 12
Silo Pharma, Inc. Advances Clinical Study Analyzing Effects of Psilocybin on Inflammation Silo Pharma, Inc. announced a progress update on its sponsored research study with the University of California, San Francisco (UCSF) examining psilocybin’s effect on inflammatory activity in humans. The clinical study evaluates three populations of patients suffering from Parkinson's disease, bipolar disorder, and chronic pain. For each patient population, the clinical studies involve preparation therapy, two separate dosing sessions with psilocybin, and integration therapy. At the Clinical & Translational Science Institute (CTSI) at UCSF, four blood samples are collected from each participant, one at baseline before treatment begins, one at 24 hours post dosing for each dosing session, and one at a 30-day follow up. The research team is on track to complete data collection from Parkinson's disease patients by the end of February 2023. Data collection is expected to begin in early 2023 for the bipolar study, and in April 2023 for the chronic pain study patients. The Clinical & Translational Science Institute at the University of California, San Francisco facilitates clinical and translational research to improve patient and community health. CTSI does this by providing infrastructure, services, and training to enable research to be conducted more efficiently and effectively, and in new ways. To advance its mission, the Institute develops broad coalitions and partnerships at the local, regional and national levels to enable a transformation of the research environment. Tillkännagivande • Dec 31
Silo Pharma Announces Positive Study Results of SPU- 21 for Arthritis Silo Pharma, Inc. announced positive interim data from its dose optimization study of SPU-21 joint homing peptidesfor subcutaneous administration of anti-arthritic agents. Silo Pharma is pursuing a development plan utilizingits liposomal joint homing peptides as a potential therapy for rheumatoid arthritis (RA). In the most recent phase of this ongoing animal study, tests were conducted to evaluate the disease-suppressive effects of an SPU-21 peptide-guided anti-arthritis drug versus the drug alone. The drug used in the study was dexamethasone (DEX), a corticosteroid used for its anti-inflammatory and immunosuppressant effects. Earlier results of the same study successfully demonstrated that the subcutaneous (SC) route of liposomal administration (small needle injection into shallow soft tissue just under the layer of skin) is well-suited for use in targeted drug delivery of anti-arthritic agents. Silo Pharma is advancing the development of SPU-21 liposomal joint homing peptides in collaboration with the University of Maryland, Baltimore (UMB). Tillkännagivande • Nov 22
Silo Pharma, Inc. Initiates Study of Novel Joint Homing Peptide in Human Tissue Silo Pharma, Inc. announced its plans to initiate a pilot study of its novel joint homing peptides targeting rheumatoid arthritis (RA), designated as SPU-21, in human synovial tissue surrounding joints and tendons. The three-month study will assess the binding affinity of the peptide in healthy human and RA synovial tissue. Initial data from the study is expected during the first quarter of 2023. Under a commercial evaluation license and option agreement with the University of Maryland, Baltimore (UMB), Silo Pharma is advancing the development of UMB’s liposomal homing peptide to deliver targeted therapeutics that could include psilocybin. The proven ability of the peptide to target inflamed epithelium suggest they could be used to target drug delivery. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. The peptides also have potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis, could be customizable for potential use in delivering nanoparticles for precise imaging, and can be used to treat autoimmune diseases, including but not limited to RA. Rheumatoid arthritis is among the most common autoimmune diseases in the U.S., affecting approximately 1.5 Americans. A 2022 report published by Precedence Research states that the global rheumatoid arthritis drugs market is expected to reach $70 billion by 2030, growing at a compound annual growth rate of 1.7%. In addition to SPU-21, Silo Pharma holds a license agreement with UMB for a central nervous system (CNS) homing peptide for the investigation and treatment of multiple sclerosis and other rare neurological diseases designated as SPU-16. Board Change • Nov 16
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Chairman, President & CEO Eric Weisblum is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Reported Earnings • Nov 13
Third quarter 2022 earnings released: US$0.49 loss per share (vs US$3.28 profit in 3Q 2021) Third quarter 2022 results: US$0.49 loss per share (down from US$3.28 profit in 3Q 2021). Net loss: US$983.2k (down 115% from profit in 3Q 2021). Over the last 3 years on average, earnings per share has increased by 64% per year but the company’s share price has fallen by 51% per year, which means it is significantly lagging earnings. Tillkännagivande • Nov 12
Silo Pharma Achieves New Milestone for SP-26 Therapeutic -Initiates IND Enabling Study of Topical Ketamine Formulation Silo Pharma, Inc. announced initial dosing in its IND-enabling study of SP-26, its novel time-released, topical formulation of ketamine. The objective of this safety evaluation study, conducted by Experimur, a Frontage Company, is to evaluate the tolerability of the SP-26 compound to establish a maximum tolerated dose. The new drug is intended to treat fibromyalgia, a chronic condition causing widespread musculoskeletal pain accompanied by memory issues, sleep problems and fatigue. Silo Pharma recently began working with a regulatory partner to prepare a pre-Investigational new drug (IND) package submission to the U.S. Food and Drug Administration (FDA). The Company intends to pursue the 505(b)(2) regulatory pathway for SP-26. Valuation Update With 7 Day Price Move • Nov 11
Investor sentiment deteriorated over the past week After last week's 16% share price decline to US$3.26, the stock trades at a trailing P/E ratio of 2.5x. Average trailing P/E is 13x in the Biotechs industry in the US. Total loss to shareholders of 89% over the past three years. Board Change • Nov 01
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Chairman, President & CEO Eric Weisblum is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Oct 21
Silo Pharma, Inc. Announces Data Supporting Therapeutic Potential of SPC -14 for Alzheimer's Disease in Pre-Clinical Study Silo Pharma, Inc. announced proof-of-concept data supporting the therapeutic potential of SPC-14 as a treatment for Alzheimer's disease, as demonstrated in a mouse model. The research was conducted as part of a sponsored research agreement with Columbia University in New York. SPC-14, a novel drug that combines an FDA-approved therapeutic with ketamine, is in development for the treatment of dementia related to Alzheimer's disease. Initial data from its SPC-14 research studies shows that chronic dosing of SPC-14 resulted in increased memory in AD mice and had no negative weight effects on the subjects. Valuation Update With 7 Day Price Move • Oct 11
Investor sentiment improved over the past week After last week's 15% share price gain to US$5.94, the stock trades at a trailing P/E ratio of 4.5x. Average trailing P/E is 15x in the Biotechs industry in the US. Total loss to shareholders of 69% over the past three years. Board Change • Oct 11
High number of new and inexperienced directors There are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. 1 highly experienced director. Chairman, President & CEO Eric Weisblum is the most experienced director on the board, commencing their role in 2013. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors. Tillkännagivande • Oct 11
Silo Pharma Initiates Toxicity Study of Proprietary Ketamine Formulation for Treatment of Fibromyalgia Silo Pharma, Inc. announced that it has initiated a preclinical toxicity study of its novel time-released, dosage controlled formulation of ketamine, designated as SP-26, for the treatment of fibromyalgia. In the safety evaluation study, the tolerability of the SP-26 compound will be determined in a mini pig study using an ascending (descending) dosing regimen. Data from the study is expected in the first quarter of 2023.Silo Pharma recently announced that it is working with a regulatory partner to prepare an FDA Pre-Investigational New Drug (IND) package for SP-26. The Company intends to pursue a 505(b)(2) regulatory pathway for the drug candidate. Tillkännagivande • Oct 04
Silo Pharma, Inc. Initiates FDA Pre-Investigational New Drug (IND) Package for Time-Released Ketamine Technology Silo Pharma, Inc. announced that it is working with Premier Consulting as its regulatory partner to assist with the preparation of a pre-Investigational New Drug (IND) package and meeting request with the United States Food and Drug Administration (FDA) for a novel topical formulation of ketamine, designated as SPC-26, for the treatment of fibromyalgia. Premier Consulting will assist the Company with the development of its nonclinical, clinical, clinical pharmacology, and biopharmaceutics strategy and program to be proposed to the FDA. The submission of a pre-IND meeting request for collaborative discussions with the FDA will be made in anticipation of the filing a clinical IND package. In collaboration with joint venture partner Zylö Therapeutics, Inc. (ZTI), Silo Pharma is pursuing the clinical development of ketamine using ZTI’s Z-pod™ technology. Pre-clinical studies have shown that the Z-pod can hold and distribute ketamine in a time-released manner, and the Company has determined to pursue fibromyalgia as an initial indication. Fibromyalgia is a chronic condition causing pain to the connective tissues through the body including muscles, ligaments, and tendons. Musculoskeletal pain is often accompanied by sleep difficulties, fatigue, mood disorders, and problems with memory and concentration. Fibromyalgia affects about 4 million American adults, or about 2% of the adult population. According to Fortune Business Insights1, the fibromyalgia treatment market is projected to grow from $764.1 million in 2020 to $1,414.4 million in 2027, at a CAGR of 9.2% in the 2020-2027 period. Tillkännagivande • Jul 28
Silo Pharma, Inc. Announces Positive Results from its Topically Administered Formulation of Ketamine Silo Pharma, Inc . announced that its topically administered Ketamine reached a positive end point in an animal study. Silo’s formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, and mechanical hyperalgesia was reduced on day seven at the pre-dose time point. These results indicate that the dosing of Ketamine using a patent protected delivery system with Silo Pharma’s partner, Zylo Therapeutics, yielded positive results in reducing neuropathic nerve pain in a small animal study. Tillkännagivande • Jul 13
Silo Pharma, Inc. Announces Positive Results in Subcutaneous Delivery of Its Novel Liposomes to Treat Arthritic Patients Silo Pharma, Inc. . announced that its novel liposomes reached a positive endpoint in animal studies showing effectiveness and reduced toxicity using a subcutaneous delivery method. In previous work, ART-1-Cy7-liposomes injected i.v. demostrated homing to arthritic joints and 4 hours was an optimal time point for high fluorescence intensity in the hind paws. The results of this new study show that the time kinetics and quantitative aspects of liposomes administered subcutaneous were not much different from that of liposomes injected i.v. In fact, despite some initial delay, the signal strength showed a trend towards a higher level in subcutaneous than in i.v. Tillkännagivande • May 20
Silo Pharma Announces Successful Dosing of Patients Suffering from Parkinson's Disease in Psilocybin Study Silo Pharma, Inc. announced that it in conjunction with the University of California San Francisco (UCSF), researchers have successfully dosed patients suffering from Parkinson’s disease. As part of this study, the researchers are collecting blood samples to determine the effects of psilocybin on inflammatory markers of patients who have exhibited signs of Parkinson’s. This study is taking place at The Translational Psychedelic Research (TrPR) Program at UCSF. TrPR brings together scientists and care providers across disciplines to understand how psilocybin, LSD, ketamine, MDMA and related compounds impact the brain and other organ systems. The goal of TrPR is to accelerate progress towards impactful and accessible psychedelic treatments. Tillkännagivande • Apr 21
Silo Pharma Produces SPU-21 Liposomes for Rheumatoid Arthritis Study Silo Pharma, Inc. . announced that it has produced its first batch of Liposomes for use in a preclinical study that will be conducted by Frontage Laboratories, a CRO (contract research organization). The ability of the SPU-21 to target inflamed epithelium suggest they could be used to target drug delivery. Silo’s novel joint homing peptides can be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis (RA). This approach could enhance the therapeutic effect of current and future therapies and decrease potential toxicity despite systemic administration of the drug. SPU-21 has potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. Tillkännagivande • Mar 05
Silo Pharma, Inc. Enters into Exclusive Option Agreement with the University of Maryland, Baltimore for Patented Homing Peptides Targeting Rheumatoid Arthritis Silo Pharma Inc. announced that it has executed an exclusive option agreement with the University of Maryland, Baltimore to explore a novel invention generally known as joint-homing peptides for use in the investigation and treatment of arthritogenic processes. The ability of the peptides to target inflamed endothelium suggests they could be used to target drug delivery to the diseased joints. This approach could enhance the therapeutic effect of current and future therapies and decrease potential systemic toxicity despite systemic administration of the drug. These peptides have the potential for the development of fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. The peptides could also be customizable and used to deliver nanoparticles for precise imaging. In addition, these novel joint-homing peptides may be used to treat autoimmune diseases, including but not limited to Rheumatoid Arthritis. Tillkännagivande • Feb 17
Silo Pharma, Inc. Enters into A Master License Agreement with the University of Maryland, Baltimore On February 12, 2021, Silo Pharma Inc. entered into a master license agreement (the “UMB License Agreement”) with the University of Maryland, Baltimore (“UMB”) pursuant to which UMB granted the Company an exclusive, worldwide (the “Territory”), sublicensable, royalty-bearing license to certain intellectual property (i) to make, have made, use, sell, offer to sell, and import certain licensed products and (ii) to use the invention titled, “Central nervous system-homing peptides in vivo and their use for the investigation and treatment of multiple sclerosis and other neuroinflammatory pathology” and UMB’s confidential information to develop and perform certain licensed processes for the therapeutic treatment of neuroinflammatory disease (“Licensed Field”). Pursuant to the UMB License Agreement, the Company shall pay UMB (i) a license fee in the high five-digit figures, (ii) certain event-based milestone payments, (iii) royalty payments in the low single digits or mid single digits, depending on net revenues, and (iv) a tiered percentage of sublicense income. The UMB License Agreement will remain in effect until the later of: (a) the last patent covered under the UMB License Agreement expires, (b) the expiration of data protection, new chemical entity, orphan drug exclusivity, regulatory exclusivity, or other legally enforceable market exclusivity, if applicable, or (c) ten (10) years after the first commercial sale of a licensed product in that country, unless earlier terminated in accordance with the provisions of the UMB License Agreement. Tillkännagivande • Feb 11
Silo Pharma Inc. announced that it expects to receive $4.276 million in funding Silo Pharma Inc. (OTCPK:SILO) announced that it has entered into securities purchase agreements with certain institutional and accredited investors for a private placement of 4,276 series C convertible preferred stocks at a price of $1,000 per share for gross proceeds of $4,276,000 on February 9, 2021. The preferred stocks are convertible into common shares at a fixed conversion price of $0.30 per share. The company will also issue warrants to purchase 14,253,333 of common shares exercisable for a period of five years from the date of issuance at an exercise price of $0.30 per share. The transaction is expected to close on or about February 11, 2021, subject to satisfaction of customary closing conditions. Tillkännagivande • Jan 28
Silo Pharma Reaches Terms with University of Maryland Baltimore for Exclusive License of Central Nervous Homing Peptide for Neuroinflammatory Disease Silo Pharma Inc. announced it has exercised its option to take an exclusive license for patents owned by the University of Maryland Baltimore for the treatment of Neuroinflammatory Disease. The exercise of the option agreement allows for Silo to negotiate an exclusive patent license agreement. The option agreement included pre-negotiated business terms for the exclusive patent license, which we expect to finalize shortly. Tillkännagivande • Jan 12
Silo Pharma Inc. Announces Licensing Agreement with Aikido Pharma Inc Silo Pharma Inc. announced a licensing agreement with up-front payment valued at $1 Million. The license agreement with Aikido Pharma Inc., grants Akido an exclusive, royalty-bearing license to certain intellectual property owned by Silo Pharma to develop therapeutics for the treatment and complications of cancer. In consideration for granting the license, Silo Pharma received a one-time cash payment of $500,000 and shares of newly designated Convertible Preferred Stock valued at $500,000 on the date of execution of the license. Silo Pharma will also be entitled to potential royalty payments on Net Sales (as defined in the Agreement) in the event that the licensed property is commercially developed. Tillkännagivande • Jan 08
Silo Pharma Inc. Receives One Million Dollars in Up Front Licensing Deal for its Psilocybin Cancer Therapeutic Applications in a Combination of Cash and Equities Silo Pharma Inc. announced that it has entered into an agreement to license technology covered by provisional patent applications filed by Silo Pharma with the United States Patent and Trademark Office in use for patients suffering with cancer. Silo Pharma’s patent applications relates to using a novel peptide with Psilocybin as a therapeutic. Tillkännagivande • Dec 17
Silo Pharma, Inc. Appoints Charles B. Nemeroff to Scientific Advisory Board Silo Pharma Inc. announced that its Board of Directors has named clinical researcher and professor, Dr. Charles B. Nemeroff, M.D., Ph.D., to its Scientific Advisory Board. Dr. Nemeroff is chair and professor with the Department of Psychiatry and Behavioral Sciences at the University of Texas at Austin Dell Medical School. He also directs the Institute for Early Life Adversity Research within the Department of Psychiatry and Behavioral Sciences as part of the Mulva Clinic for the Neurosciences. Prior to joining Dell Medical School, Dr. Nemeroff was chair of the Department of Psychiatry and Behavioral Sciences and clinical director of the Center on Aging at the University of Miami Miller School of Medicine in Miami, Florida. Tillkännagivande • Dec 10
Silo Pharma Inc. Appoints Peter Hendricks to its Scientific Advisory Board Silo Pharma Inc. announced that its Board of Directors has named Dr. Peter Hendricks, Ph.D. to its newly formed Scientific Advisory Board. Dr. Peter Hendricks is an Associate Professor in the University of Alabama at Birmingham’s Health and Behavior department where he has led studies and authored a number of published research articles that explore the therapeutic impacts of psychedelic drugs, including psilocybin. UAB is one of the few universities in the world currently investigating the medicinal benefits of psilocybin. Dr. Hendricks has served as Associate Professor at UAB since 2010. He has focused his research on the interplay between psychedelic-assisted psychotherapy and a host of sociological issues such as criminality, substance abuse, and suicide. His most current area of research focused on the evaluation of the therapeutic potential of classic and novel phenethylamine, tryptamine, and lysergamide psychedelics. Tillkännagivande • Dec 03
Silo Pharma Announces Plans for a Phase 2B Investigator Lead Study Using Psychedelics Psilocybin and Lysergic Acid Diethylamide (“LSD”) to Treat Parkinson’S Disease Silo Pharma Inc. announced that it has entered into an investigator-sponsored study agreement with Maastricht University of the Netherlands. The research project is a clinical study to examine the effects of repeated low doses of psilocybin and LSD on cognitive and emotional dysfunctions in Parkinson’s disease and to understand its mechanism of action. The Phase 2B study is a human study to be conducted on a sufficient number of patients, the primary purpose of which is to evaluate the safety and efficacy of psilocybin and LSD on patients suffering from Parkinson’s disease. The primary objective of this trial is to investigate the effects of repeated low doses of psilocybin and LSD on well-being and affect (self-rated), emotional and cognitive attention (computer tasks), and biological markers of neuroplasticity. Secondary objectives are to investigate the effects of repeated low doses of psilocybin and LSD on cognitive performance measures of memory and executive functioning, known to be impaired in Parkinson’s disease (computer tasks) and emotion regulation Parkinson’s symptoms, and biological markers of well-being (immune system, cortisol). Tillkännagivande • Nov 17
Silo Pharma, Inc. Names Joshua Woolley to Newly Formed Scientific Advisory Board Silo Pharma Inc. announced that its Board of Directors has named scientific research investigator Dr. Joshua Woolley, M.D. /Ph.D. to its newly formed Scientific Advisory Board.
Dr. Joshua Woolley M.D. /Ph.D. is an Associate Professor in Residence, Department of Psychiatry at the University of California, San Francisco (UCSF) as well as a staff psychiatrist in Mental Health at the San Francisco Veterans Affairs Medical Center (SFVAMC). Throughout his career, Dr. Woolley has moved between the clinical and research laboratory, focusing his area of study on understanding and treating social cognitive deficits across various mental illness diagnoses. Dr. Woolley is currently the principal investigator and founder of the Bonding and Attunement in Neuropsychiatric Disorders (BAND) Laboratory. The mission of the BAND Lab is to understand the mechanisms of social connection in general, understand why people with mental illness have trouble with social connection, and develop and test novel treatments for these deficits. Dr. Woolley has been studying the mechanisms underlying social cognitive deficits found across different mental illness diagnoses including schizophrenia, posttraumatic stress disorder and substance use disorders. He is also investigating the psychobiological mechanisms underlying group cohesion and trust as well as developing pharmacologically enhanced group interventions for these psychiatric illnesses. Tillkännagivande • Nov 10
Silo Pharma, Inc. Launches Scientific Advisory Board with Appointment of Matthew Johnson of John Hopkins University Silo Pharma Inc. announced that it has formed a Scientific Advisory Board for evaluating opportunities to advance strategies related to the use of psychedelic and psilocybin drug therapies. The company appointed addiction medicine and drug dependence researcher Dr. Matthew W. Johnson, Ph.D. as a member of the advisory board. Dr. Matthew W. Johnson, Ph.D., a Professor of Psychiatry and Behavioral Sciences at Johns Hopkins. 
